ProVise Management Group LLC Buys 186 Shares of IQVIA Holdings Inc. (NYSE:IQV)

ProVise Management Group LLC increased its position in IQVIA Holdings Inc. (NYSE:IQV) by 8.0% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,504 shares of the medical research company’s stock after purchasing an additional 186 shares during the quarter. ProVise Management Group LLC’s holdings in IQVIA were worth $633,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the business. AdvisorNet Financial Inc increased its position in shares of IQVIA by 327.6% in the fourth quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company’s stock worth $29,000 after purchasing an additional 95 shares during the period. Rise Advisors LLC bought a new position in shares of IQVIA in the first quarter valued at approximately $31,000. BKM Wealth Management LLC bought a new position in IQVIA during the fourth quarter valued at about $32,000. Riverview Trust Co purchased a new position in IQVIA in the first quarter valued at approximately $32,000. Finally, Activest Wealth Management purchased a new stake in IQVIA during the fourth quarter valued at about $35,000. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Stock Performance

NYSE:IQV traded down $0.28 on Friday, hitting $224.57. The stock had a trading volume of 1,066,345 shares, compared to its average volume of 1,065,908. IQVIA Holdings Inc. has a 52-week low of $167.42 and a 52-week high of $261.73. The stock has a market cap of $40.92 billion, a price-to-earnings ratio of 30.46, a price-to-earnings-growth ratio of 2.10 and a beta of 1.49. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 2.02. The business’s 50-day simple moving average is $219.73 and its two-hundred day simple moving average is $228.90.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, May 2nd. The medical research company reported $2.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.19 by $0.11. The company had revenue of $3.74 billion during the quarter, compared to analyst estimates of $3.69 billion. IQVIA had a net margin of 9.01% and a return on equity of 29.17%. As a group, research analysts predict that IQVIA Holdings Inc. will post 10.11 earnings per share for the current year.

Wall Street Analyst Weigh In

IQV has been the subject of several research reports. Evercore ISI cut their target price on IQVIA from $250.00 to $230.00 and set an “outperform” rating for the company in a research note on Tuesday, July 9th. Truist Financial decreased their price objective on IQVIA from $297.00 to $292.00 and set a “buy” rating for the company in a report on Friday, May 3rd. StockNews.com upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Monday. Robert W. Baird lowered their target price on shares of IQVIA from $241.00 to $235.00 and set a “neutral” rating for the company in a report on Wednesday, July 10th. Finally, The Goldman Sachs Group initiated coverage on IQVIA in a research report on Thursday, June 6th. They set a “buy” rating and a $270.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $255.73.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.